biosimilar
-
USV partners with Biogenomics to launch insulin for diabetes
INSUQUICK has been produced with indigenous technology USV and Biogenomics announced the launch of INSUQUICK, India’s first biosimilar Insulin Aspart, which…
Read More » -
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of biosimilars susiness from Viatris in 70+ countries Biocon Biologics has completed the integration of the acquired…
Read More » -
Kotak Special Situations Fund invests Rs 1070 Cr in Biocon
Biocon will use the proceeds to finance Biocon Biologics’ acquisition of the biosimilars business of its partner Viatris to create…
Read More » -
Lupin, DKSH sign exclusive licensing and supply agreement
To market five biosimilar candidates in the Philippines Lupin has signed an exclusive license and supply agreement with DKSH to…
Read More » -
Sandoz announces new global ‘Act4Biosimilars’ initiative
To improve patient access and increase adoption by at least 30% in 30+ countries by 2030 Sandoz announced the launch…
Read More » -
Biocon Biologics to acquire Viatris’ biosimilars assets
The acquisition will be for up to $3.335 billion in stock and cash Biocon Biologics, a subsidiary of Biocon has…
Read More » -
Cipla in JV with Kemwell Biopharma for biosimilars
A joint venture company will be incorporated with an aim to enter the respiratory biosimilars space. Cipla and Kemwell Biopharma…
Read More » -
Biocon Biologics, Viatris receive US FDA nod for Semglee
Semglee is used in the treatment of diabetes Biocon Biologics and Viatris announced that the US Food and Drug Administration…
Read More » -
Global biosimilars market poised to reach $79.2 billion by 2026
The sector will grow at a CAGR of 17.3 per cent Frost & Sullivan’s recent analysis, Access to New Therapy…
Read More »